Pa Notification Prevymis
Policy governs prior authorization/notification requirements for Prevymis (letermovir) prophylaxis in specified transplant populations (allogeneic HSCT recipients who are CMV-seropositive and certain high-risk kidney transplant recipients). It includes initial approval criteria and instructions for reauthorization (which requires appeal).
10/2025 annual review with updated formatting and reference; no change to clinical intent.
10/2024 background updated with expanded FDA approved indications in pediatric population; no changes to coverage criteria.
7/2023 updated background with additional FDA approved indication and updated coverage criteria.
Coverage Summary
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.